Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.

摘要: Abstract Background Observational studies have demonstrated an association between excision repair cross-complementation group 1 (ERCC1) expression level and health outcomes in patients with advanced non–small-cell lung cancer (NSCLC) treated platinum-based regimens. This analysis presents pooled estimates of from these to better elucidate the prognostic role ERCC1 NSCLC. Methods A systematic literature search was conducted using MEDLINE, EMBASE, American Society Clinical Oncology (ASCO) annual meeting databases June 1995 December 2010. Included were evaluated for clinical, methodological, statistical heterogeneity. Pooled analyses fixed random effects models. Results In high versus low patients, results a significantly lower response (risk ratio [RR], 0.80, 0.66-0.98) higher risk death (hazard [HR], 2.04, (1.48-2.80)), respectively. Subgroup significant heterogeneity by measurement method (I 2 : 90.7%, P = 0.001) patient population ethnicity 66%, 0.003). Conclusion study's findings support hypothesis that is associated rate overall survival (OS) NSCLC chemotherapy. Heterogeneity subgroup demonstrates need standardized methods classify level, evaluating OS non-Asian populations, interaction other known factors